American Association for Cancer Research (AACR) Annual Meeting 2021 (Week 1)

Virtual 10 April 2021 - 15 April 2021

Copanlisib-rituximab combo extends PFS in relapsed indolent non-Hodgkin lymphoma

02 Jun 2021 by

The combination of copanlisib and rituximab extended progression-free survival (PFS) compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma, results of the phase III CHRONOS-3 trial showed.

Copanlisib-rituximab combo extends PFS in relapsed indolent non-Hodgkin lymphoma

02 Jun 2021

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021 by

The anti-PD-1 antibody tislelizumab may help improve patient outcomes vs docetaxel as second- or third-line treatment for advanced or metastatic non–small-cell lung cancer (NSCLC) regardless of histology or PD-L1 expression, interim findings from the phase III RATIONALE 303 study have shown.

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021 by

First-line treatment with the bispecific fusion protein tebentafusp demonstrated an overall survival (OS) benefit in patients with human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma (mUM), according to a phase III, open-label trial presented at AACR 2021.

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021

Atezolizumab-bevacizumab combo continues to win in advanced HCC

12 May 2021 by

The combination of the immune checkpoint inhibitor atezolizumab and the angiogenesis inhibitor bevacizumab continues to demonstrate significant clinical benefits vs the oral multikinase inhibitor sorafenib in patients with unresectable hepatocellular carcinoma (HCC), according to updated results from the IMbrave150 trial.

Atezolizumab-bevacizumab combo continues to win in advanced HCC

12 May 2021

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021 by

The anti-PD-1 monoclonal antibody sintilimab outperformed docetaxel as second-line treatment for advanced and metastatic squamous non-small-cell lung cancer (NSCLC), according to the results of the phase III ORIENT-3 trial presented at AACR 2021.

Sintilimab shows potential as second-line treatment option for squamous NSCLC

12 May 2021

Ovarian cancer survivors at risk for mental health problems

11 May 2021 by

Ovarian cancer survivors were more likely to experience mental health problems, such as anxiety, depression, and adjustment disorder, within the first 2 years after their cancer diagnosis compared with those without ovarian cancer, according to a study presented at AACR 2021.

Ovarian cancer survivors at risk for mental health problems

11 May 2021

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021 by

Updated analyses of the phase III IMvigor130 trial presented at AACR 2021 revealed the overall survival (OS) benefit of atezolizumab for previously untreated locally advanced or metastatic urothelial carcinoma (mUC), be it alone or with platinum/gemcitabine chemotherapy (CT).

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021

Healthy lifestyle could reduce lethal prostate cancer risk

07 May 2021 by

Having a healthy lifestyle could reduce the risk of lethal prostate cancer even in men with a high genetic risk for the disease, a recent study showed.

Healthy lifestyle could reduce lethal prostate cancer risk

07 May 2021

Nivolumab-platinum chemo combo improves response in early NSCLC

03 May 2021 by

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Nivolumab-platinum chemo combo improves response in early NSCLC

03 May 2021